Rilpivirine and products containing St John's wort should not be coadministered as significant decreases in rilpivirine plasma concentrations may occur which may result in loss of therapeutic effect of rilpivirine. Coadministration is not recommended in the product labels for rilpivirine. However, a recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (<1 mg/day) of St John’s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp). Coadministration may be considered with St John’s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of 1 mg or less.